Figure 6 | Leukemia

Figure 6

From: Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Figure 6

Comparison of platelet function in ibrutinib-treated CLL (n=64), ibrutinib-treated mantle cell lymphoma (MCL; n=7), CC292-treated CLL (n=6), CLL control (n=13) and X-linked agammaglobulinemia (XLA; n=1) patients. Median RIPA values: ibrutinib/CLL (19.5 U, range: 0–199 U), ibrutinib/MCL (20.5 U, range: 9–97 U), CC292/CLL (23 U, range: 3–49 U), Control CLL (37 U, range: 6–94 U) and XLA (56 U, range 33–79 U).

Back to article page